Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Recently, Standard & Poor’s Rating Services (S&P) raised the long-term issuer credit rating (ICR) of the operating subsidiaries of American Express Co. ( AXP - Analyst Report ) or AmEx to “A-” from “BBB+.” Additionally, the rating agency affirmed the ICR of the holding company at “BBB+/A-2” and the short-term ICR of its operating subsidiaries at “A-2.” The outlook for all ratings remains stable.
The affirmation of AmEx’s ratings was based on the company’s consistent revenue growth even amid the global economic downturn and regulatory pressures. Revenue growth was driven by fee income, which remained comparatively unaffected by asset quality.
Moreover, the company’s asset quality also remained superior to other card companies given its focus on affluent customers. Additionally, the addition of direct-to-consumer deposits, which S&P considers stronger than wholesale funding but weaker than branch originated deposits, has enhanced AmEx’s funding profile.
Amex’s improving customer spending trends, superior asset quality and strong earnings resulted in the stable outlook on the ratings despite a slow economic recovery and higher regulatory restrictions. Moreover, S&P expects a moderate deterioration in the company’s asset quality from the current strong levels.
However, if AmEx’s risk-adjusted capital ratio increases to 10% from the current level of 7.6%, then the ratings can be revised upward. Alternatively, if the company’s profitability declines consistently, thereby straining the capital balance, or if there are any unfavorable regulatory, legislative or legal changes, then a downward revision of the ratings is imminent.
The Zacks Consensus Estimate for AmEx’s second-quarter 2012 earnings currently stands at $1.10 per share, up 2.5% year over year. For 2012, earnings are expected to be about $4.34 per share, reflecting growth of 5.3% over 2011.
AmEx primarily competes with Discover Financial Services ( DFS - Analyst Report ) , Visa Inc. ( V - Analyst Report ) and MasterCard Incorporated ( MA - Analyst Report ) . The company carries a Zacks #3 Rank, which translates into a short-term Hold rating. We also maintain our long-term Neutral recommendation on the stock.
Read the full reports :
Analyst Report on AXP
Analyst Report on MA
Analyst Report on V
Analyst Report on DFS